ANORO ELLIPTA 55 micrograms/22 micrograms inhalation powder, pre-dispensed *

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 28 July 2021

File name

ie&ukni-pil-anoro-issue1draft1_1627466276.pdf

Reasons for updating

  • Change to section 6 - date of revision
  • Change to other sources of information section

Updated on 23 February 2021

File name

ie-pil-anoro-issue16draft1-medie_1614100964.pdf

Reasons for updating

  • Change to section 6 - manufacturer

Updated on 16 December 2020

File name

ie-pil-anoro-issue15draft1_1608137007.pdf

Reasons for updating

  • Change to MA holder contact details

Updated on 16 December 2020

File name

ie-pil-anoro-issue15draft1_1608136999.pdf

Reasons for updating

  • Change to MA holder contact details

Updated on 04 October 2019

File name

ie-spc-anoro-issue11draft1-medicines.ie_1570199021.pdf

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 02 October 2019

File name

ie-spc-anoro-issue11draft1-medicines.ie_1570006611.pdf

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 02 October 2019

File name

ie-pil-anoro-issue14draft1-medicines.ie_1570006574.pdf

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 29 January 2019

File name

ie-pil-anoro-issue13draft1 - Meds ie_1548776827.pdf

Reasons for updating

  • Change to Section 1 - what the product is
  • Change to section 1 - what the product is used for
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - use in children and adolescents
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 2 - driving and using machines
  • Change to section 3 - how to take/use
  • Change to section 3 - overdose, missed or forgotten doses
  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect
  • Change to section 5 - how to store or dispose
  • Change to section 6 - what the product contains
  • Change to section 6 - what the product looks like and pack contents
  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision

Updated on 29 January 2019

File name

ie-spc-anoro-issue10draft1 - Meds ie_1548776931.pdf

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.5 - Nature and contents of container
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 9 - Date of first authorisation/renewal of the authorisation
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 17 December 2018

File name

ie-pil-anoro-issue12draft1 - Meds ie_1545042750.pdf

Reasons for updating

  • Change to section 4 - how to report a side effect
  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision

Updated on 17 December 2018

File name

ie-spc-anoro-issue9draft1 - Meds ie_1545042803.pdf

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 20 August 2018

File name

ie-pil-anoro_1534759291.pdf

Reasons for updating

  • Change to section 6 - date of revision
  • Change to name of medicinal product

Updated on 20 August 2018

File name

ie-spc-anoro_1534759352.pdf

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Addition of Ellipta to the Tradename throughout sections of the SPC

Updated on 20 July 2017

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

SmPC section 4.8 - Addition of dysphonia as adverse reaction with uncommon frequency

Updated on 20 July 2017

File name

PIL_16004_78.pdf

Reasons for updating

  • New PIL for new product

Updated on 20 July 2017

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 20 July 2017

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 04 May 2017

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

SPC Section 4.2
Additional information on Desiccant sachet and rearrangement of text on cleaning the mouthpiece

Updated on 03 May 2017

Reasons for updating

  • Change to section 6 - date of revision
  • Change to other sources of information section

Updated on 03 February 2017

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

SPC Section 4.8
Addition of AE's:
Vision Blurred as Rare frequency
Intraocular pressure increased as Rare frequency
Paradoxical bronchospasm as Rare frequency

Updated on 31 January 2017

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 24 October 2016

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4,8 SPC
Addition of Renal AEs
Urinary retention -Rare
Dysuria - Rare
Bladder outlet obstruction -Rare

Updated on 21 October 2016

Reasons for updating

  • Change to side-effects
  • Change to date of revision
  • Addition of information on reporting a side effect.

Updated on 04 August 2016

Reasons for updating

  • Previous version of PIL reinstated

Updated on 03 August 2016

Reasons for updating

  • Change to side-effects
  • Change to date of revision

Updated on 08 April 2016

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company



Update section 4.8 to include Glaucoma as an adverse event with the frequency “not known”.

Updated on 07 April 2016

Reasons for updating

  • Change to side-effects
  • Change to date of revision

Updated on 29 January 2016

Reasons for updating

  • Change to date of revision
  • Addition of manufacturer

Updated on 24 December 2015

Reasons for updating

  • Change to date of revision
  • Change to MA holder contact details

Updated on 08 October 2015

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.2 - Paediatric population: minor administrative change

Section 4.5 - Metabolic and transporter based interactions: Minor correction

Section 4.8 - Addition of new adverse reactions: Hypersensitivity reactions including: Rash (uncommon), Anaphylaxis, angioedema, and urticaria (rare), Tremor (uncommon), Dysgeusia (uncommon), Palpitations (uncommon)

Section 5.1 - Amendment to section regarding clinical information on the use of rescue medication

Section 9 - Addition of the date of grant of the marketing authorisation

Updated on 08 October 2015

Reasons for updating

  • Change to side-effects
  • Change to further information section
  • Change to date of revision

Updated on 09 April 2015

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 6.3 - Shelf life
  • Change to section 6.4 - Special precautions for storage
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Description of change to SPC:
4.2          Posology and method of administration – additional information to advise the patient to not open the tray until they are ready to
                inhale a dose and for the patient to write the discard date on the Ellipta label.

4.8          Undesirable effects – update HPRA AE reporting details
6.3          Shelf life - clarity on shelf life

6.4          Special precautions for storage – clarity on shelf life and advising patient to write the discard date on the Ellipta label.

Updated on 08 April 2015

Reasons for updating

  • Change to storage instructions
  • Change to date of revision
  • Addition of information on reporting a side effect.
  • Correction of spelling/typing errors

Updated on 16 May 2014

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

None provided

Updated on 15 May 2014

Reasons for updating

  • New PIL for new product